Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

ProQR Therapeutics (PRQR) Short-Term Debt repayments (2019 - 2022)

ProQR Therapeutics recorded quarterly Short-Term Debt repayments of -$384152.5 in Q3 2022, down 0.84% quarter-over-quarter from -$380939.2 in Q2 2022, and up 6.12% year-over-year from -$361984.6 in Q3 2021.

ProQR Therapeutics' Short-Term Debt repayments history runs 4 years deep, the most recent figure standing at -$384152.5 for Q3 2022.

  • In Q3 2022, Short-Term Debt repayments rose 6.12% year-over-year to -$384152.5; the TTM figure through Sep 2022 stood at -$1.7 million (down 112.08% YoY), while the FY2021 annual figure was -$970385.7, down 40.48% from the prior year.
  • Short-Term Debt repayments came in at -$384152.5 for Q3 2022 at ProQR Therapeutics, down from -$380939.2 in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of -$223.0 in Q1 2020 to a low of -$646466.5 in Q1 2022.
  • A 4-year average of -$283575.4 and a median of -$322484.4 in 2019 frame the typical range for Short-Term Debt repayments.
  • Across the five-year window, Short-Term Debt repayments jumped 99.93% in 2020 and sank 127557.95% in 2021, its largest moves.
  • ProQR Therapeutics' Short-Term Debt repayments stood at -$442755.1 in 2019, then soared by 83.03% to -$75114.3 in 2020, then sank by 239.62% to -$255105.5 in 2021, then slumped by 50.59% to -$384152.5 in 2022.
  • According to Business Quant data, Short-Term Debt repayments over the past three periods registered -$384152.5, -$380939.2, and -$646466.5 for Q3 2022, Q2 2022, and Q1 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 102,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 ProQR Therapeutics 174.11 Mn 66.54 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2022 -384,152.52
Sep 30, 2022 -384,152.52
Jun 30, 2022 -380,939.24
Jun 30, 2022 -380,939.24
Mar 31, 2022 -646,466.53
Mar 31, 2022 -646,466.53
Dec 31, 2021 -255,105.52
Dec 31, 2021 -255,105.52
Sep 30, 2021 -409,212.70
Sep 30, 2021 -409,212.70
Jun 30, 2021 -16,859.80
Jun 30, 2021 -16,859.80
Mar 31, 2021 -284,671.72
Mar 31, 2021 -284,671.72
Dec 31, 2020 -75,114.26
Dec 31, 2020 -75,114.26
Sep 30, 2020 -274,498.15
Sep 30, 2020 -274,498.15
Jun 30, 2020 -115,653.31
Jun 30, 2020 -115,653.31
Mar 31, 2020 -223.00
Mar 31, 2020 -223.00
Dec 31, 2019 -442,755.07
Dec 31, 2019 -442,755.07
Sep 30, 2019 -322,691.71
Sep 30, 2019 -322,691.71
Jun 30, 2019 -322,484.42
Jun 30, 2019 -322,484.42
Mar 31, 2019 -322,802.60
Mar 31, 2019 -322,802.60